<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85715">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01967550</url>
  </required_header>
  <id_info>
    <org_study_id>194-P-308</org_study_id>
    <secondary_id>2012-004024-38</secondary_id>
    <nct_id>NCT01967550</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)</brief_title>
  <official_title>A 4-week, Randomized, Double-blind, Multi-center, Vehicle-controlled, Parallel Group Study to Assess the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel for the Relief of Signs and Symptoms in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of diclofenac DDEA 2.32 % in patient
      suffering from knee osteoarthritis (OA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Measure: Pain On Movement (POM)</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>POM will be assessed by subject on a 100 mm Visual Analog Scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure POM regarding onset of efficacy</measure>
    <time_frame>6, 12, 30, 36 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>POM will be assessed by subject on a 100 mm Visual Analog Scale (VAS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>diclofenac diethylamine, DDEA 2.32% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>diclofenac diethylamine, DDEA 2.32% gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclofenac diethylamine, DDEA 2.32% gel</intervention_name>
    <arm_group_label>diclofenac diethylamine, DDEA 2.32% gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Male or female ≥ 50 years old; 2. Symptomatic OA of one or both knees, according
             to ACR criteria, diagnosed at least 6 months previously; 3. Pain in either knee
             originates in the knee (not referred pain from other sites, such as hip or back) and
             no other cause of pain than knee OA; 4. Have used oral NSAIDs or COXIBs for the knee
             OA pain (including aspirin if ≥ 500 mg and used in this indication), at least one
             dose per day, for not less than 10 days out of the 14 days preceding the screening
             visit and also within the 24 hours preceding the screening visit; 5. Be able to
             tolerate rescue medication with only 500 mg paracetamol (APAP) taken in doses of 1-2
             tablets up to a maximum of 6 tablets (3 grams) per day for the duration of the study

        Exclusion Criteria:

        - 1. Partial or total replacement of either knee joint, past or planned/expected during
        study duration.

        2. OA of the knee due to other underlying conditions, such as gout, chondrocalcinosis,
        hemochromatosis, joint infections, neuropathia, or severe traumatic joint damage (however,
        common risk factors, such as obesity and past meniscectomy or ligament rupture and repair,
        are allowed); 3. History of systemic inflammatory (autoimmune) disease (rheumatoid
        arthritis, systemic psoriasis, systemic lupus erythematosus, systemic sclerosis, etc.) or
        laboratory values indicative of such disease with subsequent diagnosis by a physician; 4.
        Fibromyalgia within the previous year; 5. Allergy or asthma to diclofenac, APAP, aspirin,
        other NSAIDs or any of the ingredients in the gel (i.e. isopropyl alcohol, propylene
        glycol, or butylhydroxytoluene), or any other contraindication for the study drug or the
        rescue medication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Clinical Project Leader</last_name>
    <phone>+41223635293</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Bad Durrheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Novartis Clinical Project Leader</last_name>
      <phone>+41223635293</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Hersfeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Novartis Clinical Project Leader</last_name>
      <phone>+41223635293</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Novartis Clinical Project Leader</last_name>
      <phone>+41223635293</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Novartis Clinical Project Leader</last_name>
      <phone>+41223635293</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Novartis Clinical Project Leader</last_name>
      <phone>+41223635293</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Novartis Clinical Project Leader</last_name>
      <phone>+41223635293</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>October 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symptomatic knee OA Kellgren-Lawrence grade 1-3</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
